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A B S T R A C T
Background
Malaria is still a major public health problem, partly because the pathogenesis of its major
complication, cerebral malaria (CM), remains incompletely understood. However tumor
necrosis factor (TNF) is thought to play a key role in the development of this neurological
syndrome, as well as lymphotoxin a (LT).
Methods and Findings
Using an in vitro model of CM based on human brain–derived endothelial cells (HBEC-5i), we
demonstrate the anti-inflammatory effect of LMP-420, a 2-NH2-6-Cl-9-[(5-dihydroxyboryl)-
pentyl] purine that is a transcriptional inhibitor of TNF. When added before or concomitantly to
TNF, LMP-420 inhibits endothelial cell (EC) activation, i.e., the up-regulation of both ICAM-1 and
VCAM-1 on HBEC-5i surfaces. Subsequently, LMP-420 abolishes the cytoadherence of ICAM-1-
specific Plasmodium falciparum–parasitized red blood cells on these EC. Identical but weaker
effects are observed when LMP-420 is added with LT. LMP-420 also causes a dramatic reduction
of HBEC-5i vesiculation induced by TNF or LT stimulation, as assessed by microparticle release.
Conclusion
These data provide evidence for a strong in vitro anti-inflammatory effect of LMP-420 and
suggest that targeting host cell pathogenic mechanisms might provide a new therapeutic
approach to improving the outcome of CM patients.
PLoS Medicine | www.plosmedicine.org September 2005 | Volume 2 | Issue 9 | e2450885
Open access, freely available online PLoSMEDICINE
Introduction
Malaria results in up to 2.5 million deaths annually, with
young children and pregnant women at greatest risk.
Plasmodium falciparum causes the most severe and life-threat-
ening form of malaria in man, cerebral malaria (CM). This
complex cerebral syndrome includes several features in
pediatric patients, notably the sequestration of parasitized
red blood cells (PRBC) [1,2], platelets and leucocytes [3] in
brain capillaries and post-capillary venules, systemic endo-
thelial activation [4], and, as recently described, increased
numbers of circulating endothelial microparticles (MP) [5].
Numerous studies provide evidence for the key role of
tumor necrosis factor (TNF) in the pathogenesis of CM, and a
clear relationship has been established between plasma
concentrations of TNF levels and cerebral pathology [6–8].
In experimental CM, TNF-beta, now called lymphotoxin a
(LT), was recently shown to be the principal mediator of
pathogenesis [9]. Indeed, LT and TNF belong to the same
family, interact with a common receptor, and could act
together during the pathogenesis [10]. Both cytokines can
activate endothelium and be responsible for an increase of
MP release by human brain endothelium (S. C. Wassmer, V.
Combes, F. Candal, I. Juhan-Vague, and G. E. Grau,
unpublished data) [11].
In this report we test the anti-inﬂammatory activity of a
newly designed 2-NH2-6-Cl-9-[(5-dihydroxyboryl)-pentyl] pu-
rine, named LMP-420. LMP-420 inhibits transcription of
mRNA for TNF in a variety of human cell types including
monocytes, T lymphocytes, neutrophils, adipocytes, and
endothelial cells (ECs), and has a 50% inhibitory concen-
tration (IC50) of 50 nM in human peripheral blood mono-
nuclear cells (S. Haraguchi, N. K. Day, W. Kamchaisatian, M.
Engele, S. Stenger, N. Tangsinmankong, J. W. Sleasman, S. V.
Pizzo, and G. J. Cianciolo, unpublished data). In this study,
using an in vitro co-culture model composed of human brain
microvascular EC (HBEC-5i), and FCR-3 or FCR-3–derived P.
falciparum strains, we aimed to assess the ability of LMP-420 to
inhibit in vitro TNF and/or LT effects on brain endothelium,
with particular attention to its activation, adhesiveness for
malarial parasites, and vesiculation.
Methods
Reagents
LMP-420 (2-NH2-6-Cl-9-[(5-dihydroxyboryl)-pentyl] pu-
rine) was provided as a gift from LeukoMed, Inc. of Raleigh,
North Carolina, United States. It was stored either as a dry
powder under desiccation at20 8C or at20 8C as aliquots of
a 10 mM stock solution in DMSO (tissue culture grade
dimethylsulfoxide; Sigma, St. Louis, Missouri, United States).
Human Brain Endothelial Cells (HBEC-5i)
Puriﬁed human brain microvascular EC (HBEC-5i [12])
were seeded on culture ﬂasks and grown to conﬂuence in
DME/F12 medium (pH 7.4) supplemented with 10% fetal
bovine serum, 30 lg/ml endothelial cell growth supplement,
and 10 lg/ml gentamycin.
Parasites
P. falciparum FCR3, RP8 (able to bind CSA), and PAC2 (able
to bind CD36 and ICAM-1) parasites were cultured on human
0þ erythrocytes in candle jars as described [13]. They were
grown under standard culture conditions, replacing the 10%
v/v human serum with 0.25% w/v Albumax (Life Technology,
Paris, France). PRBC preparations were enriched to 80%–
85% by gelatin ﬂotation with Plasmion (Fresenius Kabi
France, Couvier, France) [14], and suspensions were adjusted
to 53 106 PRBC/ml for cytoadherence assays.
Inhibition of HBEC ICAM-1 and VCAM-1 Up-Regulation by
LMP-420 upon TNF and LT Activation
HBEC-5i conﬂuent monolayers were left unstimulated with
and without treatment with LMP-420 (50 nM), or were
activated with TNF (overnight or 6 h, 10 ng/ml) or with LT
(overnight, 30 ng/ml), concomitantly or not with LMP-420 (50
nM), before analysis. HBEC-5i were then harvested and
labeled by indirect labeling using mouse anti-human CD54
(ICAM-1 [84H10]) and CD106 (VCAM-1 [1G1]) antibodies
(Beckman-Coulter Immunotech, Marseille, France), CD40
monoclonal antibody (mAb) (B-B20, Diaclone, Besanc¸on,
France), and CD36 mAb (FA6–152, gift from L. Edelman,
Institut Pasteur Paris) as the ﬁrst step. Secondary goat anti-
mouse Alexa488–coupled mAb (Molecular Probes, Eugene,
Oregon, United States) was added as the second step. A
nonspeciﬁc isotype-matched mouse IgG1 (Beckman-Coulter
Immunotech) was used for all controls. Cells were then
resuspended in PBS before ﬂow cytometry analysis on a
Coulter Epics XL (Coultronics France, Margency, France).
The area corresponding to HBEC-5i was deﬁned, and mean
ﬂuorescence intensities of the positive cell populations were
measured for each antigen.
Effect of LMP-420 on Several Parasite Strains
Cytoadherence to Activated HBEC
For cytoadherence assays, HBEC-5i were plated on 1% w/v
gelatin-coated 12-well IFA slides and allowed to reach
conﬂuence. These cells were incubated for 18 h prior to the
experiment, in the presence or absence of TNF (50 ng/ml) or
LT (overnight, 30 ng/ml), concomitantly or not with LMP-420
(50 nM). EC were then washed with RPMI medium (pH 6.8)
and incubated for 90 min at 37 8C with the parasite strains
(ratio PRBC:EC was 50:1). Slides were then washed to remove
non-adherent PRBC, and the remaining cells were ﬁxed by
incubation in 2.5% glutaraldehyde for 30 min, and bound
RPBC were quantitated by microscopic analysis.
Effect of LMP-420 on HBEC Vesiculation upon TNF or LT
Stimulation
HBEC-5i were seeded and grown to conﬂuence in 12-well
culture plates. Cells were then left unstimulated or activated
by TNF (100 ng/ml) or LT (100 ng/ml), concomitantly or not
with LMP-420 (50nM), for 6 h. Culture supernatants were
then collected and centrifuged at 1500 3 g for 15 min to
discard dead EC and debris. Endothelial microparticles were
labeled using annexin V-FITC and then resuspended in
binding buffer (Beckman-Coulter Immunotech) as previously
described [15].
Statistical Analysis
Statistical analyses were performed with GraphPad Prism
version 4.0 for Windows, GraphPad Software (San Diego,
California, United States. Data were analyzed by the Kruskall-
Wallis and Dunn’s pairwise tests. Results in the text are
expressed as medians, interquartile ranges (IQR), and ranges
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of individual experimental groups. A value of p , 0.05 was
considered signiﬁcant.
Results
We ﬁrst investigated the inhibitory activity of LMP-420, the
structure of which is illustrated in Figure 1, on HBEC-5i
activation, i.e., cell adhesion molecule up-regulation upon
TNF or LT stimulation. Among the major molecules present
at the surface of EC (detailed in S. C. Wassmer, V. Combes, F.
J. Candal, I. Juhan-Vague, and G. E. Grau, unpublished data),
HBEC-5i in resting conditions were found to express
constitutive cell adhesion molecules such as ICAM-1 and
VCAM-1, and both were markedly up-regulated by TNF
(Figure 2). In contrast, upon LT stimulation, only ICAM-1 was
signiﬁcantly up-regulated. The expression of CD40 was
weakly induced by both TNF and LT, and CD36 was not
detected on the surface of either resting or stimulated HBEC-
5i. When added to resting cells, LMP-420 did not modify the
expression of the surface molecules studied here. However,
when LMP-420 was added 2 h before or simultaneously with
TNF or LT, up-regulations observed for ICAM-1 and/or
VCAM-1 with both stimuli were dramatically inhibited
(Dunn’s test, p , 0.01 in each condition), and the weak
induction of CD40 by the two cytokines was abrogated.
We then investigated the consequences of such an
inhibition on parasite cytoadherence to cerebral endothe-
lium. To this end, we used PRBC infected with the FCR3
strain of P. falciparum, and subpopulations derived from it,
selected for their adhesion to speciﬁc receptors. Thus, the
RP8 subpopulation bound only to chondroitin sulfate A
(CSA, which was found to be constitutively expressed by
HBEC-5i), and the PAC2 subpopulation was selected for its
capacity to adhere to ICAM-1 and CD36 [16]. HBEC-5i were
cultured and left unstimulated or stimulated with TNF or LT,
concomitantly or not with LMP-420, as described. After
addition of PRBC, the slides were washed, and bound PRBC
were counted on ﬁve randomly selected ﬁelds (0.28 mm2).
Although the binding of CSA-speciﬁc-PRBC to resting or
TNF-stimulated EC was constant in each condition, the level
of ICAM-1/CD36-speciﬁc-PRBC binding was signiﬁcantly
higher in the presence of TNF as well as when cells were
stimulated by LT (Dunn’s test, p , 0.01; Figure 3A and 3B).
However, under both conditions in the presence of LMP-420,
this PAC2-PRBC binding increase was abrogated (Dunn’s test,
p , 0.01 for both TNF and LT; Figure 3A and 3B), and no
statistical differences were observed between the cytoadher-
ence in resting condition and upon LT- or TNF-stimulation
in the presence of LMP-420 (p¼ 1 and p¼0.067, respectively).
Even if there is no evidence of any differences in these
experiments, it does not preclude the possibility that there
are residual effects of TNF and/or LT in the presence of LMP-
420. The FCR3 strain, composed of both CSA- and ICAM-1/
CD36-speciﬁc subpopulations, exhibited a higher basal bind-
ing level (median: 705 PRBC/mm2; IQR: 110; range: 730.3 to
770.6 PRBC/mm2) than those of these two subclones taken
separately (median: 448.5 PRBC/mm2; IQR: 79.2; range: 330.9
to 538.6 PRBC/mm2; and median: 239 PRBC/mm2; IQR: 74.25;
range: 150.0 to 310.5 PRBC/mm2, respectively). The FCR3
strain’s cytoadherence was increased upon both TNF and LT
stimulation, but was signiﬁcantly reduced in the concomitant
presence of the cytokines and LMP-420 (Dunn’s test, p , 0.01
for both TNF and LT; Figure 3A and 3B), and once again, no
statistical differences were observed between the cytoadher-
ence in resting condition and upon LT- or TNF-stimulation
in the presence of LMP-420 (p ¼ 0.4 and p ¼ 0.294,
respectively).
To assess the blebbing and the shedding of MP from the
HBEC-5i surface upon cytokine stimulation, cells were
stimulated with TNF or LT, simultaneously with or without
LMP-420. We quantitated the inhibitory effect of LMP-420 on
activated HBEC-5i vesiculation by ﬂow cytometry analysis.
Upon both LT and TNF stimulation, HBEC-5i were shown to
produce signiﬁcantly higher MP numbers than in resting
conditions (Dunn’s test, p , 0.001). In the presence of LMP-
Figure 1. Structure of LMP-420 (2-NH2-6-Cl-9-[(5-Dihydroxyboryl)-Pentyl]
Purine)
DOI: 10.1371/journal.pmed.0020245.g001
Figure 2. Inhibitory Effect of LMP-420 on TNF-Induced Up-Regulation of ICAM-1 and VCAM-1
HBEC-5i were left unstimulated or were activated with LMP-420 alone, TNF alone, TNF with LMP-420, LT alone, or LT with LMP-420. After an overnight
incubation, cells were detached and analyzed by flow cytometry after immunolabeling for ICAM-1, VCAM-1, and CD40. Results are expressed as dotplots
of mean fluorescence intensity of surface expression of the antigens measured in six experiments (Dunn’s test, ** corresponds to p , 0.01).
DOI: 10.1371/journal.pmed.0020245.g002
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420, the MP release was shown to be signiﬁcantly reduced for
both conditions of stimulation (Dunn’s test, p , 0.001), and
no differences were observed between TNF and LT (Figure 4).
Discussion
Our results demonstrate that LMP-420, a newly discovered
anti-inﬂammatory molecule, potently reduces endothelial
activation, endothelial adhesiveness for P. falciparum-PRBC,
and endothelial MP release, three major features of CM. To
this end, we used a recently described in vitro CM lesion
model based on the human brain microvascular EC line,
HBEC-5i.
Our studies analyzed the effect of concomitant addition of
LMP-420 and TNF or LT upon HBEC-5i phenotype mod-
iﬁcation. TNF and LT belong to the same family and interact
with a common receptor, and it has been demonstrated that
both cytokines may up-regulate the expression of the
adhesion surface molecules ICAM-1 and VCAM-1 (S. C.
Wassmer, V. Combes, F. J. Candal, I. Juhan-Vague, and G. E.
Grau, unpublished data). In the presence of LMP-420
however, these up-regulations were markedly inhibited.
Because LMP-420 has been shown to inhibit the release of
both TNF and MCP-1 from LPS-activated PBMC, its effect on
LT has not been shown so far. LMP-420 is a particularly
potent inhibitor of TNF production, inhibiting up to 98% (S.
Haraguchi, N. K. Day, W. Kamchaisatian, M. Engele, S.
Stenger, N. Tangsinmankong, J. W. Sleasman, S. V. Pizzo,
and G. J. Cianciolo, unpublished data).
We have investigated the effect of such inhibition of
endothelial adhesion molecule up-regulation in the presence
of pro-inﬂammatory cytokines on PRBC cytoadherence.
After TNF or LT stimulations, we performed cytoadherence
assays on HBEC-5i, with several subpopulations of P.
falciparum FCR3 strains selected for their receptor speciﬁc-
ities. The presence of LMP-420 concomitantly with TNF led
to an abrogation of both the FCR3 and ICAM-1/CD36-speciﬁc
PRBC cytoadherence increase observed when HBEC-5i were
stimulated with TNF alone. This abrogation might be due to
the inhibition of ICAM-1 up-regulation on EC surface,
resulting from the addition of TNF and LMP-420, as
described above. The cytoadherence of the CSA-speciﬁc
PRBC subpopulation was not affected when HBEC-5i were
previously activated with TNF or with TNF and LMP-420.
These results are consistent with our previous data, demon-
strating that HBEC-5i exhibit a stable and constant expres-
sion of CSA, which is not affected by a prior stimulation by
TNF (S. C. Wassmer, V. Combes, F. J. Candal, I. Juhan-Vague,
and G. E. Grau , unpublished data). Because the FCR3 parasite
strain is a mixture of both previously used subpopulations
[16], its basal binding level was higher than for CSA-speciﬁc
or ICAM-1/CD36-speciﬁc PRBC subpopulations taken sepa-
rately. However, its increased cytoadherence upon TNF-
stimulation and its inhibition in the concomitant presence of
TNF and LMP-420 probably reﬂects the ICAM-1-mediated
cytoadherence of the ICAM-1/CD36-speciﬁc PRBC subpopu-
lation. Indeed, because CD36 is lacking on HBEC-5i mem-
brane and ICAM-1 expression dropped in the presence of
TNF and LMP-420, the number of binding sites might be
dramatically reduced. This could explain the ICAM-1/CD36-
Figure 3. LMP-420 Inhibits TNF- and LT-Induced Increase of PRBC
Cytoadherence
HBEC-5i were cultured until confluence was reached and were left
resting or activated as described earlier. Cytoadherence assays were then
performed with FCR3-P. falciparum strain, and RP8 and PAC2 sub-
populations selected for their ability to bind only CSA and ICAM-1/CD36,
respectively (A and B). Results of six determinations in five experiments
are expressed in bound PRBC, after two washing steps after the assay
(Dunn’s test, ** corresponds to p , 0.01).
DOI: 10.1371/journal.pmed.0020245.g003
Figure 4. Inhibitory Effect of LMP-420 on LT- and TNF-Induced Increase
of MP Release
HBEC-5i were cultured and left resting or stimulated with TNF, TNF with
LMP-420, LT, or LT with LMP-420 for 6 h before analysis. MP production
was quantified by flow cytometry for each condition. Results (four
determinations in four experiments) are expressed in numbers of MP
labeled with annexin V-FITC, extracted from culture supernatants of 103
HBEC-5i (Dunn’s test, *** corresponds to p , 0.001).
DOI: 10.1371/journal.pmed.0020245.g004
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speciﬁc PRBC subpopulation cytoadherence decrease, lead-
ing to a FCR3 binding level similar to the level observed with
the CSA-speciﬁc PRBC subpopulation. Indeed, CSA expres-
sion is not affected by TNF or LT, and its speciﬁc parasite
cytoadherence was constant in both conditions. Similar
abrogation of increased binding was observed for both
FCR3 and ICAM-1/CD36-speciﬁc PRBC subpopulations when
HBEC-5i were stimulated by LT in the presence of LMP-420
versus LT alone. These results suggest a dual speciﬁcity of the
LMP-420 molecule, which can act on two of the majors
cytokines involved in CM pathogenesis [10], leading in vitro
to a reduction of the PRBC cytoadhesion of P. falciparum
populations binding to ICAM-1. Because the degree of
binding of these ICAM-1-speciﬁc PRBC was found to be
highest in CM patients [17], we hypothesize that decreasing
the cytoadhesion of these PRBC to endothelium in vivo might
be beneﬁcial.
Finally, we analyzed the effect of LMP-420, added simulta-
neously with TNF or LT, on endothelial vesiculation, a
recently described marker of severity in pediatric CM
patients. Upon both TNF and LT activation, HBEC-5i showed
an increase of the MP release, and LMP-420 addition led to a
signiﬁcant, but partial, reduction of the vesiculation for both
stimulation conditions. This vesiculation increase has been
shown to be strongly associated with a fatal outcome in
Malawian children who died of CM [5], and although its cause
still remains unclear, the in vivo abrogation of MP release
from activated endothelium may have a protective effect. Our
data suggest that anti-inﬂammatory compounds, such as
LMP-420, might provide a new way to inhibit this vesicu-
lation, whether induced by TNF or LT.
LMP-420, a low molecular weight purine-based compound,
exhibits anti-inﬂammatory activity that may be useful in
targeting the wide variety of diseases in which TNF and its
related family members play a role. TNF is a pleiotropic
cytokine playing key roles in inﬂammation, resistance to
infection, and cancer. Besides its beneﬁcial actions, the
pathogenic effects of TNF are evident in a wide variety of
conditions, including CM. Several molecules inhibiting TNF,
such as monoclonal antibody [18] or pentoxyﬁlline [19], have
been tested in clinical trials, but failed to improve signiﬁ-
cantly the disease outcome. This could be explain by the fact
that LT was recently demonstrated to also play a crucial role
in the pathogenesis of this cerebral syndrome [9,10]. The data
herein provide evidence for a dual inhibitory effect of LMP-
420 on both TNF and LT in an in vitro model of CM lesion,
when added before or simultaneously with both cytokines.
Moreover, in the current context, efforts are being made to
identify mechanisms regulating cytokine production, espe-
cially at the mRNA stability level [20,21]. LMP-420 is a
molecule able to inhibit transcription of mRNA for TNF and
LT in a variety of human cell types including monocytes, T
lymphocytes, neutrophils, adipocytes, and EC, by interfering
with responses involving the RelA (p65) component of NF-jB
(G. Cianciolo, unpublished data).
In terms of potential side effects of anti-TNF therapies,
LMP-420 has the advantage of the pharmacological control
provided by a small molecule. The biological half-life of LMP-
420 (based on studies in mice) is approximately 12 h. Thus,
treatment could be suspended if clinical parameters wors-
ened. The currently marketed TNF antagonists are designed
to ‘‘bind and neutralize’’ all circulating TNF, which may also
hinder immune responsiveness to some degree. Dose-
response curves on LPS-activated human peripheral blood
leukocytes indicate that even at 500 nM and 5000 nM (10-fold
and 100-fold the IC50 dose, respectively), LMP-420 inhibits
only 93% and 98% of the released TNF. Thus, the fact that a
small amount of TNF may still be produced may actually have
more of a physiological effect and allow the immune system
to respond to the infectious agent by blunting the patho-
logical concentrations of TNF that occur. We believe this
aspect is extremely important, as developed earlier [22].
The ﬁndings presented here provide evidence that LMP-
420 might be considered as a new therapeutic way for CM.
Indeed, although there are currently three marketed TNF
antagonist products (etanercept [Enbrel], a soluble TNF
receptor [23]; inﬂiximab [Remicade] humanized anti-TNF
monoclonal antibody [24]; and adalimumab,[Humira] fully
human anti-TNF monoclonal antibody [25]), none of them
were described to present inhibitory effects on LT, and all
three are large proteins. In addition to their being very costly,
these molecules are less likely to cross the blood-brain
barrier, whereas a small molecule like LMP-420 might have
greater accessibility to the brain than protein-based ther-
apeutics. Moreover, because of their proteinaceous nature,
they require refrigerated shipping and storage. This is not the
case for LMP-420, which is a small organic molecule, highly
temperature stable. Finally, LMP-420 is of the same general
class of compounds (purine nucleoside analogs) that has been
safely used in humans for several decades, and thus could
represent a novel, stable, and efﬁcient therapeutic way to
improve the outcome of CM patients. Although we recognize
that experimental results observed in cell culture in vitro are
not necessarily predictive of potential efﬁcacy in either
animal models or man, we believe that the results presented
herein support the further evaluation of therapeutic strat-
egies aimed at minimizing the pathologic host responses to
Plasmodia-infected erythrocytes. Although it is entirely
possible that the inﬂammatory process may be irreversibly
advanced by the time a patient presents for treatment, there
is currently insufﬁcient information to know at what clinical
stage intervention loses it value or could even become
harmful. The availability of potent, small molecular weight
cytokine inhibitors will hopefully allow us to determine that
information.
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Patient Summary
Background The most severe complication of malaria is when it involves
the brain, so-called cerebral malaria, and which is caused by one
particular form of the malarial parasite, Plasmodium falciparum. Cerebral
malaria occurs most frequently in children and is often fatal. Although it
is not clear exactly what all the events in cerebral malaria are, it is known
that there is inflammation, that some of the cells in the blood vessels
become stimulated, and that red cells infected with malarial parasites
adhere to the stimulated cells and get stuck in the small blood vessels of
the brain.
Why Was This Study Done? The researchers had previously identified a
compound, LMP-420, that could block the synthesis of one of the
substances that is associated with blood vessel stimulation. They wanted
to test its effect in a model of cerebral malaria.
What Did the Researchers Do and Find? They added LMP-420 to
cultures of blood vessel cells in the presence or absence of the
substances known to stimulate the blood vessel cells, as well as to a
culture of red cells infected with the malarial parasite. They found that
LMP-420 could prevent the activation of the blood vessel cells and could
partially stop the infected red cells from sticking to the blood vessel cells.
However, these results were observed only when LMP-420 was added
either before or at the same time that the substances associated with
blood vessel stimulation were present.
What Do These Findings Mean? LMP-420 may be able to act as an anti-
inflammatory substance in the blood vessels of the brain of patients
infected with malaria. One drawback, however, is that the data thus far
show efficacy only if given very early; in practice this would mean
treating patients before they had symptoms of cerebral malaria, which
might be practically difficult. However, there is no way to know from cell
culture studies whether intervention after the process has started might
benefit the final outcome. So, it will be necessary to test the compound
further before it is clear whether it will be clinically useful.
Where Can I Get More Information Online? Medline plus has many
links to information about malaria:
http://www.nlm.nih.gov/medlineplus/malaria.html
The CDC has a page on regional risks of malaria:
http://www.cdc.gov/travel/regionalmalaria/
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